Stacy C. Dilzer

TL;DR: In this article, the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients was investigated.

TL;DR: In nondiabetic obese subjects, treatment with sitagliptin 200 mg bid was generally well tolerated without associated hypoglycemia and led to maximal inhibition of plasma DPP‐4 activity, increased active GLP‐1, and reduced glycemic excursion.

TL;DR: The metabolism and excretion of [14C]sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 μCi, indicating that sitagli leptin was eliminated primarily by renal excretion.

TL;DR: Radioactivity was widely distributed in rats, with the highest concentrations in liver, kidney, lung, and spleen, and liver exhibited an extended uptake phase, peaking at 24 h with 35% of total dose in liver.

TL;DR: To determine the effects of COX-2 inhibition on glomerular filtration rate and serum and urine electrolyte balance, rofecoxib was administered to elderly patients who were receiving a sodium-restricted diet, which enhanced renal dependence on prostaglandin production.